These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35239006)

  • 1. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
    J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.
    Jameie M; Azizmohammad Looha M; Ebadi Z; Amanollahi M; Amani K; Nobahari F; Abdollahi A; Mousavi M; Pourghaz B; Harirchian MH
    BMC Neurol; 2024 Aug; 24(1):291. PubMed ID: 39164636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
    Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
    Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    Habek M; Jakob Brecl G; Bašić Kes V; Rogić D; Barun B; Gabelić T; Emeršič A; Horvat Ledinek A; Grbić N; Lapić I; Šegulja D; Đurić K; Adamec I; Krbot Skorić M
    J Neuroimmunol; 2021 Oct; 359():577696. PubMed ID: 34418815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
    Stoll S; Desai S; Levit E
    Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
    J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
    Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Schwarz T; Otto C; Jones TC; Pache F; Schindler P; Niederschweiberer M; Schmidt FA; Drosten C; Corman VM; Ruprecht K
    Mult Scler; 2022 Jun; 28(7):1041-1050. PubMed ID: 35575234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis.
    Maglione A; Francese R; Arduino I; Rosso R; Matta M; Rolla S; Lembo D; Clerico M
    Front Immunol; 2023; 14():1205879. PubMed ID: 37409134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
    Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
    Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
    Etemadifar M; Abhari AP; Nouri H; Eighani N; Salari M; Sedaghat N
    J Neurol Sci; 2023 Jan; 444():120518. PubMed ID: 36521195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
    Schiavetti I; Inglese M; Frau J; Signoriello E; Caleri F; Stromillo ML; Ferrò MT; Rilla MT; Gandoglia I; Gazzola P; Brichetto G; Pasquali L; Grimaldi L; Ulivelli M; Marinelli F; Cordera S; Clerico M; Conte A; Salvetti M; Battaglia MA; Franciotta D; Uccelli A; Sormani MP;
    Eur J Neurol; 2023 Aug; 30(8):2357-2364. PubMed ID: 37154406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.